Additionally, USP 15 and its homologue (USP 4) promote lung cancer cell proliferation by regulating SRSF1 alternative splicing, so targeting therapy against SRSF1 splicing factor may become a new strategy for SCLC treatment (Das et al., 2022). Here, SRSF1 is linked to lung carcinoma.